2. Cell Cycle/DNA Damage
  3. CDK
  4. Atuveciclib

Atuveciclib  (Synonyms: BAY-1143572)

目录号: HY-12871B 纯度: 99.80%
COA 产品使用指南

摩尔计算器

Atuveciclib (BAY-1143572) 是一种有效的，具有口服活性的高选择性 PTEFb/CDK9 抑制剂。Atuveciclib (BAY-1143572) 抑制 CDK9/CycT1，IC50 为 13 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Atuveciclib Chemical Structure

Atuveciclib Chemical Structure

CAS No. : 2923012-24-0

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2464
In-stock
5 mg ￥2240
In-stock
10 mg ￥3600
In-stock
25 mg ￥6400
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Atuveciclib:

Atuveciclib 相关抗体

Top Publications Citing Use of Products

查看 CDK 亚型特异性产品:

查看所有亚型
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM[1].

IC50 & Target[1]

CDK9/CycT1

13 nM (IC50)

CDK9/CycT1(h)

6 nM (IC50)

CDK3/CycE(h)

890 nM (IC50)

CDK2/CycE(h)

1000 nM (IC50)

CDK1/CycB(h)

1100 nM (IC50)

CDK5/p35(h)

1600 nM (IC50)

体外研究
(In Vitro)

Positive transcription elongation factor b (PTEFb) is a heterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Atuveciclib (BAY-1143572) demonstrates potent antiproliferative activity against HeLa cells (IC50=920 nM) and MOLM-13 cells (IC50=310 nM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Atuveciclib 相关抗体:
体内研究
(In Vivo)

In vivo efficacy studies in the MOLM-13 xenograft model in mice, Atuveciclib (BAY-1143572) demonstrates great potency and high antitumor efficacy. Daily administration of Atuveciclib (BAY-1143572) at 6.25 or 12.5 mg/kg results in a dose-dependent antitumor efficacy with a treatment-to-control (T/C) ratio of 0.64 and 0.49, respectively (p<0.001). In a separate experiment with a higher daily dose of 20 or 25 mg/kg Atuveciclib (BAY-1143572), antitumor efficacy with a T/C ratio of 0.41 and 0.31, respectively, is observed (p<0.001). The 25 mg/kg once daily dose is the maximum tolerated dose in nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on / two days off, results in a T/C ratio of 0.33 and 0.20, respectively (p<0.001). Treatment with Atuveciclib (BAY-1143572) is well-tolerated, as demonstrated by less than 10 % mean body weight reduction throughout the study. In an in vivo pharmacokinetic study in rats, Atuveciclib (BAY-1143572) shows low blood clearance (CLb 1.1 L/kg per hour)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

387.43

Formula

C18H18FN5O2S
CAS 号
性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
In Vitro: 

DMSO 中的溶解度 : ≥ 128.5 mg/mL (331.67 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5811 mL 12.9056 mL 25.8111 mL
5 mM 0.5162 mL 2.5811 mL 5.1622 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料
参考文献
Cell Assay
[1]

HeLa human cervical tumor cells (CCL-2) and MOLM-13 human acute myeloid leukemia cells (ACC 554) are propagated under the suggested growth conditions in a humidified 37°C incubator. Proliferation assays are conducted in 96-well plates at densities of 3000 (HeLa) and 5000 (MOLM-13) cells per well in the growth medium containing 10 % fetal calf serum (FCS). Cells are treated in quadruplicate with serial dilutions of test compounds (e.g., Atuveciclib (BAY-1143572)) for 96 h. Relative cell numbers are quantified by crystal violet staining (HeLa) or CellTitre-Glo Luminescent Cell Viability Assay (MOLM-13). IC50 values are determined by means of a four-parameter fit on measurement data which are normalized to vehicle (DMSO) treated cells (=100 %) and measurement readings taken immediately before compound exposure (=0 %)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Mice and Rats[1]
For the acute myeloid leukemia (AML) mouse model, 2×106 MOLM-13 human AML cells are inoculated subcutaneously to the left flank of female NMRI nu/nu mice (18-21 g, 5-6 weeks). For the AML model in rats, 2×106 MV4-11 human AML cells are inoculated subcutaneously to the left flank of female athymic nude rats (160-200 g, 5-6 weeks). Animals are stratified into treatment and control groups (n=8-13/group for mice, n=12/group for rats) based on primary tumor size. Treatments are started 3-13 days after tumor cell inoculation when the average tumor sizes are 23-38 mm2 and 43 mm2 for mice and rats, respectively. The 20 and 25 mg/kg once daily dose is for nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on/two days off. BAY-1143572 is administered daily oral administration of Atuveciclib (BAY-1143572) at 12 mg/kg for rats. Unless otherwise indicated, all treatments are administered orally (p.o.) and are continued until the end of the experiment. Body weight and tumor areas (longest diameter multiplied by its perpendicular) measured by caliper are determined at least twice weekly. T/C ratios are calculated by dividing the mean tumor area of the treatment group by the mean tumor area of the vehicle group at the time point when the vehicle group is sacrificed[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

Atuveciclib 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5811 mL 12.9056 mL 25.8111 mL 64.5278 mL
5 mM 0.5162 mL 2.5811 mL 5.1622 mL 12.9056 mL
10 mM 0.2581 mL 1.2906 mL 2.5811 mL 6.4528 mL
15 mM 0.1721 mL 0.8604 mL 1.7207 mL 4.3019 mL
20 mM 0.1291 mL 0.6453 mL 1.2906 mL 3.2264 mL
25 mM 0.1032 mL 0.5162 mL 1.0324 mL 2.5811 mL
30 mM 0.0860 mL 0.4302 mL 0.8604 mL 2.1509 mL
40 mM 0.0645 mL 0.3226 mL 0.6453 mL 1.6132 mL
50 mM 0.0516 mL 0.2581 mL 0.5162 mL 1.2906 mL
60 mM 0.0430 mL 0.2151 mL 0.4302 mL 1.0755 mL
80 mM 0.0323 mL 0.1613 mL 0.3226 mL 0.8066 mL
100 mM 0.0258 mL 0.1291 mL 0.2581 mL 0.6453 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Atuveciclib2923012-24-0BAY-1143572BAY1143572BAY 1143572CDKCyclin dependent kinaseInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Atuveciclib
目录号：
HY-12871B
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z